NEULANDLAB — Neuland Laboratories Share Price
0.000.00%
Last trade - 00:00- IN₹162.16bn
- IN₹161.28bn
- IN₹15.59bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 36.86 | ||
| PEG Ratio (f) | 0.87 | ||
| EPS Growth (f) | 73.81% | ||
| Dividend Yield (f) | 0.13% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 11.37 | ||
| Price to Tang. Book | 14.25 | ||
| Price to Free Cashflow | 383.8 | ||
| Price to Sales | 10.35 | ||
| EV to EBITDA | 34.64 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 25.5% | ||
| Return on Equity | 23.72% | ||
| Operating Margin | 25.46% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 7,627.11 | 9,369.13 | 9,510.77 | 11,911.98 | 15,585.81 | 16,037.51 | 20,473.13 | 18.51% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +132.21 | +106.4 | -19.31 | +151.7 | +93.9 | -22.63 | +73.81 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Neuland Laboratories Limited is an India-based company. The Company is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. The Company is an active pharmaceutical ingredient (API) manufacturing and development organization that caters to the pharmaceutical and biotech industry’s chemistry needs. It provides solutions across the full range of the pharmaceutical industry’s chemistry requirements, from the synthesis of library compounds to supplying New Chemical Entities (NCEs) and advanced intermediates at various stages in the clinical life cycle, as well as commercial launch. The Company has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its key molecules include Mirtazapine, an anti-depressant and Levetiracetam, an anti-epileptic agent. The Company’s product portfolio includes over 100 APIs across 10 diverse therapeutic areas.
Directors
- Davuluri Rao CHM (68)
- Davuluri Rao CEO (37)
- Sarada Bhamidipati CCO
- Davuluri Rao MDR (33)
- Nirmala Murthy DRC
- Bharati Rao DRC
- Christopher Cimarusti NED
- Homi Khusrokhan IND
- Humayun Dhanrajgir NID (83)
- Parampally Maiya NID (83)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 7th, 1984
- Public Since
- April 18th, 1994
- No. of Shareholders
- 29,507
- No. of Employees
- 1,648
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 12,900,500
- Address
- 'A' Block, Ground Floor, 8-2-120/113, HYDERABAD, 500033
- Web
- https://www.neulandlabs.com/
- Phone
- +91 4067611600
- Contact
- Diwakar Pingle
- Auditors
- MSKA & Associates
Upcoming Events for NEULANDLAB
Neuland Laboratories Ltd Annual Shareholders Meeting
Q1 2026 Neuland Laboratories Ltd Earnings Release
Similar to NEULANDLAB
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Neuland Laboratories share price?
As of Today at 22:14 UTC, shares in Neuland Laboratories are trading at IN₹12,300.00. This share price information is delayed by 15 minutes.
How has the Neuland Laboratories share price performed this year?
Shares in Neuland Laboratories last closed at IN₹12,300.00 and the price had moved by +73.43% over the past 365 days. In terms of relative price strength the Neuland Laboratories share price has outperformed the S&P BSE 100 Index by +63.37% over the past year.
What are the analyst and broker recommendations for Neuland Laboratories?
The overall consensus recommendation for Neuland Laboratories is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Neuland Laboratories dividend yield?
The Neuland Laboratories dividend yield is 0.11% based on the trailing twelve month period.
Does Neuland Laboratories pay a dividend?
Last year, Neuland Laboratories paid a total dividend of IN₹14.00, and it currently has a trailing dividend yield of 0.11%. We do not have any data on when Neuland Laboratories is to next pay dividends.
When does Neuland Laboratories next pay dividends?
We do not have data on when Neuland Laboratories is to next pay dividends. The historic dividend yield on Neuland Laboratories shares is currently 0.11%.
How do I buy Neuland Laboratories shares?
To buy shares in Neuland Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Neuland Laboratories?
As of the previous close price of IN₹12,300.00, shares in Neuland Laboratories had a market capitalisation of IN₹162.16bn.
Where are Neuland Laboratories shares listed?
Here are the trading details for Neuland Laboratories:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: NEULANDLAB
What kind of share is Neuland Laboratories?
Based on an overall assessment of its quality, value and momentum Neuland Laboratories is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Neuland Laboratories share price forecast for 2025?
The analyst consensus target price for shares in Neuland Laboratories is IN₹17,221.96. That is 40.02% above the last closing price of IN₹12,300.00.
Analysts covering Neuland Laboratories currently have a consensus Earnings Per Share (EPS) forecast of IN₹191.97 for the next financial year.
Find out moreWhat is the trend in the Neuland Laboratories share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neuland Laboratories. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -9%.
As of the last closing price of IN₹12,300.00, shares in Neuland Laboratories were trading -3.5% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Neuland Laboratories PE Ratio?
The Neuland Laboratories PE ratio based on its reported earnings over the past 12 months is 36.86. The shares last closed at IN₹12,300.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Neuland Laboratories?
Neuland Laboratories' management team is headed by:
- Davuluri Rao - CHM
- Davuluri Rao - CEO
- Sarada Bhamidipati - CCO
- Davuluri Rao - MDR
- Nirmala Murthy - DRC
- Bharati Rao - DRC
- Christopher Cimarusti - NED
- Homi Khusrokhan - IND
- Humayun Dhanrajgir - NID
- Parampally Maiya - NID